Early-Phase Whole-Body PK

Did you know that, on average, 83% of drug candidates never make it past the pre-clinical stage?

Don’t let your molecule become just another number. Aliri’s innovative label-free whole-body pharmacokinetics (PK) service gives you powerful early-phase insights—helping you understand efficacy directly at the site of action, flag potential safety issues earlier, and make smarter, data-driven decisions about clinical candidate selection.

Even better? This groundbreaking method is not only more cost-effective but also accelerates your timeline by 6–10 months compared to conventional approaches.